Comparison Chart COMPASS Pathways plc

Equities

Real-time Estimate Cboe BZX Other stock markets 11:30:09 2024-06-20 am EDT			5-day change	1st Jan Change
6.29 ^USD	-2.18%		-9.51%	-28.23%

Jun. 05	Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating	MT
Jun. 04	FDA panel to review psychedelic drug MDMA for first time	RE

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	COMPASS PATHWAYS PLC	Other Biotechnology & Medical Research	-2.33%	-9.51%	-28.23%	-24.34%	-	440M